Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTC Drug for Atopic Dermatitis
NCT07146971Phase 1Terminated
- Start
- Aug 2025
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Phase 1 trial in atopic dermatitis (AD) (2 arms). Primary endpoints: Skin Microbiome Composition and Diversity using qPCR analysis at 4 weeks, Trans-Epidermal Water Loss Measurement at 4 weeks and 2 more. Started Aug 2025; status: terminated.
02
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07146971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07146971.